RSV vaccine GSK3003892A

RSV vaccine GSK3003892A is an investigational respiratory syncytial virus (RSV) vaccine candidate developed by GSK. It is designed to prevent RSV infection, a major cause of lower respiratory tract disease in vulnerable populations such as infants and older adults. The vaccine utilizes a recombinant prefusion F protein antigen from the RSV virus, formulated with an adjuvant to enhance immune response. Its primary mechanism of action is to induce neutralizing antibodies against the prefusion conformation of the RSV F protein, thereby preventing viral entry into host cells. Clinical trials have focused on evaluating its safety, reactogenicity, and immunogenicity in various adult populations[3][4].